Year-end Sale % OFF 
Abstract
Clopidogel is a prodrug requiring hepatic bioactivation via cytochrome P450 isozymes (CYP2C19,CYP3A4, CYP3A5) to its pharmacologically active form. Inhibition of cytochrome P450 may interfere with metabolicactivation of clopidogrel, reducing its antiplatelet activity andpotentially increasing the risk of thrombosis. More recently, thecytochrome P450 2C19 pathway has been identified as the keypathway in clopidogrel bioactivation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
